Singapore markets closed
  • Straits Times Index

    -13.67 (-0.43%)
  • Nikkei

    -498.83 (-1.80%)
  • Hang Seng

    -354.29 (-1.35%)
  • FTSE 100

    -25.88 (-0.37%)

    -836.39 (-2.09%)
  • CMC Crypto 200

    -22.24 (-2.34%)
  • S&P 500

    -10.08 (-0.23%)
  • Dow

    -7.43 (-0.02%)
  • Nasdaq

    -63.12 (-0.43%)
  • Gold

    -6.60 (-0.36%)
  • Crude Oil

    +0.25 (+0.34%)
  • 10-Yr Bond

    -0.0270 (-2.13%)
  • FTSE Bursa Malaysia

    -18.33 (-1.21%)
  • Jakarta Composite Index

    -50.69 (-0.83%)
  • PSE Index

    -226.30 (-3.48%)

PURA Finalizes On Increased Investment In ALKM To Produce New CBD Infused Products

·2-min read

Dallas, Texas, June 14, 2021 (GLOBE NEWSWIRE) -- Puration, Inc. (OTC Pink: PURA) today finalized with Alkame Holdings, Inc. (OTC Pink: ALKM) on the previously announced commitment for PURA to increase its investment in ALKM.

In an earlier capital investment initiative, PURA acquired a five percent interest in ALKM.

PURA is working with ALKM and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) in the development of a series of new CBD infused products. PURA’s new investment will be directed at funding ALKM to formulate the products and set up the ALKM plant for producing the products. USMJ will manage marketing of the new CBD infused products.

The investment transaction is now complete. PURA has advanced funds for ALKM to formulate products and set up the ALKM plant for producing new products. While the investment, like all investments, is at risk, PURA expects the investment to ultimately result in ALKM creating new products for PURA whereby PURA’s return will come from the sale of the new products with no long-term debt or equity impact to ALKM.

For more information on Puration, visit
Puration, Inc.
Brian Shibley,
+1 (800) 861-1350

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Puration, Inc. will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting